Feedback / Questions
daraxonrasib (RMC-6236) - Revolution Medicines
https://www.globenewswire.com/news-release/2025/06/24/3104100/0/en/Revolution-Medicines-Enters-Into-2-Billion-Flexible-Funding-Agreement-with-Royalty-Pharma-to-Support-Global-Development-and-Commercialization-of-RAS-ON-Inhibitor-Portfolio-for-Pati.html
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next